Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering

Executive Summary

MeiraGTx was the first to go public in the US in June after six drug developer IPOs launched in May. With returns for this year's first-time biopharma offerings more than doubling from 9% at the end of April to 23.6% as of June 8, four new companies have filed and six have set terms for future IPOs.

Advertisement

Related Content

Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina
Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development
Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m
IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First
PRIME Dry Spell Ends As EMA Takes On Eye Disease Gene Therapy
IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose
Provention Builds On J&J Disease Interception Model
Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel